Peptides Just Got a Green Light — Here's What It Means for Telehealth Marketing

Emergency episode. Today — Thursday, April 16th — RFK Jr. and the FDA announced a major policy shift: 12 peptides are being pulled out of Category 2 and sent to PCAC for formal review starting in July. Names like BPC-157, Epitalon, GHK-Cu, MOTS-c, Semax, and Melanotan II are on the list. This isn't full approval — but it's the clearest signal yet that peptides are moving from the black market into regulated, legitimate clinical pathways.

And for Telehealth marketers and operators, this changes everything.

In this episode, Mark Militant breaks down what the shift actually means for growth in the space: why LegitScript certification is about to open up for peptide protocols (and why that's the unlock for paid media on Meta and Google), why ESPs and payment processors will start saying yes instead of no, and why Shopify and other platforms are quietly positioning for this moment. He covers the supply-side explosion coming to Telehealth, the consumer confidence flip that's about to accelerate influencer adoption and soften media narratives, and the branding opportunity for operators who want to build the Nike of longevity instead of another spammy biohacker storefront.

Mark also digs into the retention gold mine hiding in this category — why peptides are a repeat-purchase, subscription-native behavior, why lifecycle flows (onboarding, dosage reminders, progress tracking) become the core of the business, and why the savage marketers and operators are going to win this category before traditional healthcare even wakes up.

If you caught the earlier episode on why Telehealth brands are getting kicked off Klaviyo, this is the other side of the coin: the platforms are about to open up, the rules are about to get clearer, and the window to move is right now.

This feels like e-commerce in 2012 — with 2026 tools. Don't sleep on it.